BMO Capital Markets Boosts Tetraphase Pharmaceuticals, Inc. (TTPH) Price Target to $24.00
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) had its target price lifted by stock analysts at BMO Capital Markets from $13.00 to $24.00 in a research note issued on Wednesday, The Fly reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target points to a potential upside of 209.68% from the stock’s current price.
Several other research analysts have also commented on TTPH. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 6th. HC Wainwright started coverage on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, July 11th. They set a “buy” rating and a $15.00 price objective for the company. Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $8.00 to $15.00 in a research note on Wednesday, July 26th. Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Thursday, July 27th. Finally, BidaskClub lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. Tetraphase Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $12.96.
Shares of Tetraphase Pharmaceuticals (TTPH) traded up 6.90% during midday trading on Wednesday, reaching $7.75. 2,411,344 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $6.68 and its 200 day moving average price is $7.29. The company’s market cap is $395.66 million. Tetraphase Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.07). The firm had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The company’s revenue was up 28.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.47) EPS. Equities analysts anticipate that Tetraphase Pharmaceuticals will post ($2.54) earnings per share for the current fiscal year.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 17,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total transaction of $105,000.00. Following the sale, the insider now owns 17,500 shares of the company’s stock, valued at approximately $105,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 5.50% of the stock is currently owned by insiders.
A number of large investors have recently added to or reduced their stakes in TTPH. AXA purchased a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth approximately $132,000. Citadel Advisors LLC grew its position in Tetraphase Pharmaceuticals by 18.6% during the 1st quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after purchasing an additional 2,496 shares during the last quarter. Virtu KCG Holdings LLC purchased a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth approximately $147,000. Voya Investment Management LLC grew its position in Tetraphase Pharmaceuticals by 17.8% during the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 3,104 shares during the last quarter. Finally, UBS Group AG grew its position in Tetraphase Pharmaceuticals by 2.3% during the 1st quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 387 shares during the last quarter. 41.73% of the stock is currently owned by institutional investors.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.